Details of the Drug Combination

General Information of Drug Combination (ID: DC21KYE)

Drug Combination Name
Ronacaleret Plerixafor
Indication
Disease Entry Status REF
Transplantation, Stem Cell Phase 1 [1]
Component Drugs Ronacaleret   DM10ZJP Plerixafor   DMCJN1P
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ronacaleret
Disease Entry ICD 11 Status REF
Osteoporosis FB83.0 Discontinued in Phase 2 [2]
Ronacaleret Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Extracellular calcium-sensing receptor (CASR) TTBUYHA CASR_HUMAN Antagonist [4]
------------------------------------------------------------------------------------
Indication(s) of Plerixafor
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Approved [3]
Plerixafor Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
C-X-C chemokine receptor type 4 (CXCR4) TTBID49 CXCR4_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Plerixafor Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Decreases Expression [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01802892) Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023902)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 844).
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
6 Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology. 2013 Dec 15;314(2-3):209-20. doi: 10.1016/j.tox.2013.10.003. Epub 2013 Oct 21.